Você procurou por: should be interrupted (Inglês - Maltês)

cotellic treatment and vemurafenib treatment should be interrupted.
il-kura ta’ cotellic u l-kura ta’ vemurafenib għandha tiġi interrotta.

darzalex infusion should be interrupted for irrs of any severity.
l-infużjoni ta’ darzalex għandha titwaqqaf għall-irrs ta’ kwalunkwe qawwa.

iclusig should be interrupted immediately in case of vascular occlusion.
iclusig għandu jitwaqqaf immedjatament f’każ ta’ okklużjoni vaskulari.

if fistula formation occurs, sunitinib treatment should be interrupted.
jekk tifforma fistula, it-trattament b’sunitinib għandu jitwaqqaf.

treatment with these agents should be interrupted during ketek treatment.
il-kura b’dawn is-sustanzi għandha titwaqqaf waqt il-kura b`ketek.

if necessary, therapy with desirudin should be interrupted until aptt falls to less than
jekk ikun hemm bżonn, it- terapija b’ desirudin trid titwaqqaf sakemm il- livell ta ’ aptt jaqa ’ għal anqas minn darbtejn il- valur tal- kontroll, meta mbagħad, it- trattament b’ desirudin jista ’ jerġa ’ jinbeda b’ doża anqas (ara wkoll sezzjoni 4. 5).

dosing should be interrupted in patients with alt or ast of greater than times the uln.
id-dożaġġ għandu jiġi interrott f’pazjenti b’livelli ta’ alt jew ast li jkunu ogħla aktar minn 5 darbiet tal-uln.

if a diagnosis of ulcerative keratitis is confirmed, treatment should be interrupted or discontinued.
jekk tiġi kkonfermata dijanjosi ta’ keratite ulċerattiva, il-kura għandha tiġi interrotta jew titwaqqaf.

breast-feeding should be interrupted for 24 hours after treatment with this medicinal product.
it-treddigħ għandu jiġi interrott għal 24 siegħa wara t-trattament b’dan il-prodott mediċinali.

if the administration is considered necessary, breastfeeding should be interrupted and the expressed feeds discarded.
jekk l-għoti jkun ikkunsidrat neċessarju, it-treddigħ għandu jitwaqqaf u l- ħalib espress għandu jintrema.

if a diagnosis of ulcerative keratitis is confirmed, treatment with cetuximab should be interrupted or discontinued.
jekk tkun ikkonfermata dijanjosi ta’ keratite ulċerattiva, kura b’cetuximab għandha tiġi interrotta jew imwaqqfa.

treatment with these agents should be interrupted during ketek treatment (see section 4.5).
il-kura b’dawn il-mediċini trid titwaqqaf waqt il-kura b’ketek (ara sezzjoni 4.5).

in the event of serious infection or severe haematological toxicity mabcampath should be interrupted until the event resolves.
fil-każ ta’ infezzjoni serja jew tossiċità ematoloġika severa mabcampath għandu jiġi interrott sakemm il-każ jiġi riżolt.

tarceva dosing should be interrupted if changes in liver function are severe (see section 4.8).
l-iddożar ta’ tarceva għandu jitwaqqaf jekk il-bidliet fil-funzjoni tal-fwied huma severi (ara sezzjoni 4.8).

if administration is considered necessary, breast-feeding should be interrupted for 3 days and substituted by formula feeding.
jekk l-għoti jiġi kkonsidrat li hu meħtieġ, it-treddigħ għandu jiġi interrot għal 3 t’ijiem u għandu jiġi sostitwit bil-ħalib tat-trab.

for alt or ast elevations > 3– 5 x uln, confirmed by repeat testing, roactemra treatment should be interrupted.
għal żidiet ta ’ alt jew ast ta ’ > 3– 5 x uln, ikkonfermati minn ittestjar ripetut, kura b’ roactemra għandha titwaqqaf.

if neutropenia develops, dosing with mycophenolate mofetil teva should be interrupted or the dose reduced (see section 4.4).
jekk tiżviluppa n-newtropenja, mycophenolate mofetil teva għandu jiġi mwaqqaf jew id-doża mnaqqsa (ara sezzjoni 4.4).

grade 2 (intolerable) or grade ≥3 photosensitivity: cotellic and vemurafenib should be interrupted until resolution to grade ≤1.
fotosensittività ta’ grad 2 (intollerabbli) jew ta’ grad ≥3: cotellic u vemurafenib għandhom jiġu interrotti sakemm ikun hemm titjib għal grad ≤1.